Rather than representing a specific signature of AD pathophysiology (e.g., Aβ- or tau-mediated mechanisms), these pathways appear to be activated by heterogeneous triggers, including those manipulated in mouse models of HD, ALS, SCA1, and other neurodegenerative disorders. This evidence concerns the gene MAPT and Alzheimer disease.